Sugi Predict

Sugi Predict / Compounds / SCHEMBL9939755

SCHEMBL9939755

SCHEMBL9939755

Cn1cnc(S(=O)(=O)Nc2cccc(N/C(=N\C(=O)c3ccc(Cl)cc3)NCC(C)(C)C)n2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 1/20 0.41
▸ IRS1 P35568 1/20 0.38
▸ GAB1 Q13480 1/20 0.38
▸ FBP1 P09467 1/20 0.38
▸ CXCR2 P25025 2/20 0.37
▸ GLO1 Q04760 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ CCR2 P41597 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.36
▸ SLC6A9 P48067 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ HSD17B1 P14061 2/20 0.34
▸ HSD17B2 P37059 2/20 0.34
▸ LMNA P02545 1/20 0.34
▸ PIK3CG P48736 2/20 0.33
▸ HSD11B1 P28845 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9939767 0.84 HSD11B1 (0.43) L3MBTL1KDM4ERXFP1ALDH1A1LMNA
SCHEMBL9939768 0.82 RXFP1 (0.43) L3MBTL1RXFP1ALDH1A1LMNAHSD11B1
SCHEMBL9939437 0.82 RXFP1 (0.39) L3MBTL1KDM4ERXFP1LMNAHSD11B1
SCHEMBL16621985 0.80 FBP1 (0.38) FBP1L3MBTL1RXFP1LMNAHSD11B1
SCHEMBL16621987 0.80 NAMPT (0.42) L3MBTL1KDM4ERXFP1MAPK1SMN1; SMN2
SCHEMBL16621982 0.79 RXFP1 (0.40) L3MBTL1RXFP1ALDH1A1HSD11B1
SCHEMBL9939557 0.79 RXFP1 (0.47) KDM4ERXFP1ALDH1A1SMN1; SMN2LMNA
SCHEMBL16621984 0.78 RXFP1 (0.46) TSHRRXFP1ALDH1A1MAPK1SMN1; SMN2
SCHEMBL16621981 0.73 RXFP1 (0.42) L3MBTL1RXFP1SMN1; SMN2HSD11B1
SCHEMBL9939466 0.69 GRM4 (0.38) TSHRRXFP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9370507-B2 Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2016-06-21 — — US disclosed
US-9370507-B2 Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2016-06-21 — — US disclosed
US-20150335625-A1 PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION 2015-11-26 — — US disclosed
US-20150335625-A1 PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION 2015-11-26 — — US disclosed
US-9000014-B2 Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-04-07 — — US disclosed
US-9000014-B2 Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-04-07 — — US disclosed
WO-2012078869-A1 PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORPORATION (US) 2012-06-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150335625-A1 PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF ATP5F1A, ATP5ME, ATP5F1B SCN9A 2799/4885IRS1 3631/4885GAB1 2546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.